Academic Journal
Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
| العنوان: | Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives |
|---|---|
| المؤلفون: | Yau H, Kinaan M, Quinn SL, Moraitis AG |
| المصدر: | Biologics: Targets & Therapy, Vol Volume 11, Pp 115-122 (2017) |
| بيانات النشر: | Dove Medical Press, 2017. |
| سنة النشر: | 2017 |
| المجموعة: | LCC:Medicine (General) |
| مصطلحات موضوعية: | octreotide, octreotide LAR, neuroendocrine tumor, somatostatin analogue, NETTER-1, PROMID, RADIANT-2, Medicine (General), R5-920 |
| الوصف: | Hanford Yau,1 Mustafa Kinaan,2 Suzanne L Quinn,3 Andreas G Moraitis3 1Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA; 2Division of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA; 3Division of Endocrinology, Diabetes, and Metabolism, Orlando VA Medical Center, Orlando, FL, USA Abstract: Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Octreotide, the first synthetic somatostatin analog, was initially used for the management of gastrointestinal symptoms associated with functional carcinoid tumors. Its commercial development over time led to long-acting repeatable octreotide acetate, a long-acting version that provided greater administration convenience. Recent research demonstrates that octreotide’s efficacy has evolved beyond symptomatic management to targeted therapy with antitumoral effects. This review examines the history and development of octreotide, provides a synopsis on the classification, grading, and staging of neuroendocrine tumors, and reviews the evidence of long-acting repeatable octreotide acetate as monotherapy and in combination with other treatment modalities in the management of non-pituitary neuroendocrine tumors with special attention to recent high-quality Phase III trials. Keywords: carcinoid, everolimus, neuroendocrine tumor, octreotide LAR, somatostatin analog, ITMO, NETTER-1, PROMID, RADIANT-2 |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1177-5491 |
| Relation: | https://www.dovepress.com/octreotide-long-acting-repeatable-in-the-treatment-of-neuroendocrine-t-peer-reviewed-article-BTT; https://doaj.org/toc/1177-5491 |
| URL الوصول: | https://doaj.org/article/1d3c8f6693434240b731c33422227443 |
| رقم الانضمام: | edsdoj.1d3c8f6693434240b731c33422227443 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.1d3c8f6693434240b731c33422227443 906 3 Academic Journal academicJournal 905.701843261719 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1d3c8f6693434240b731c33422227443&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/1d3c8f6693434240b731c33422227443 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=11775491&ISBN=&volume=ume%2011&issue=&date=20171201&spage=115&pages=115-122&title=Biologics: Targets & Therapy&atitle=Octreotide%20long-acting%20repeatable%20in%20the%20treatment%20of%20neuroendocrine%20tumors%3A%20patient%20selection%20and%20perspectives&id=DOI: [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Yau+H%22">Yau H</searchLink><br /><searchLink fieldCode="AR" term="%22Kinaan+M%22">Kinaan M</searchLink><br /><searchLink fieldCode="AR" term="%22Quinn+SL%22">Quinn SL</searchLink><br /><searchLink fieldCode="AR" term="%22Moraitis+AG%22">Moraitis AG</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Biologics: Targets & Therapy, Vol Volume 11, Pp 115-122 (2017) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Dove Medical Press, 2017. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2017 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Medicine (General) ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22octreotide%22">octreotide</searchLink><br /><searchLink fieldCode="DE" term="%22octreotide+LAR%22">octreotide LAR</searchLink><br /><searchLink fieldCode="DE" term="%22neuroendocrine+tumor%22">neuroendocrine tumor</searchLink><br /><searchLink fieldCode="DE" term="%22somatostatin+analogue%22">somatostatin analogue</searchLink><br /><searchLink fieldCode="DE" term="%22NETTER-1%22">NETTER-1</searchLink><br /><searchLink fieldCode="DE" term="%22PROMID%22">PROMID</searchLink><br /><searchLink fieldCode="DE" term="%22RADIANT-2%22">RADIANT-2</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine+%28General%29%22">Medicine (General)</searchLink><br /><searchLink fieldCode="DE" term="%22R5-920%22">R5-920</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Hanford Yau,1 Mustafa Kinaan,2 Suzanne L Quinn,3 Andreas G Moraitis3 1Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA; 2Division of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA; 3Division of Endocrinology, Diabetes, and Metabolism, Orlando VA Medical Center, Orlando, FL, USA Abstract: Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Octreotide, the first synthetic somatostatin analog, was initially used for the management of gastrointestinal symptoms associated with functional carcinoid tumors. Its commercial development over time led to long-acting repeatable octreotide acetate, a long-acting version that provided greater administration convenience. Recent research demonstrates that octreotide’s efficacy has evolved beyond symptomatic management to targeted therapy with antitumoral effects. This review examines the history and development of octreotide, provides a synopsis on the classification, grading, and staging of neuroendocrine tumors, and reviews the evidence of long-acting repeatable octreotide acetate as monotherapy and in combination with other treatment modalities in the management of non-pituitary neuroendocrine tumors with special attention to recent high-quality Phase III trials. Keywords: carcinoid, everolimus, neuroendocrine tumor, octreotide LAR, somatostatin analog, ITMO, NETTER-1, PROMID, RADIANT-2 ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1177-5491 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.dovepress.com/octreotide-long-acting-repeatable-in-the-treatment-of-neuroendocrine-t-peer-reviewed-article-BTT; https://doaj.org/toc/1177-5491 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/1d3c8f6693434240b731c33422227443" linkWindow="_blank">https://doaj.org/article/1d3c8f6693434240b731c33422227443</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.1d3c8f6693434240b731c33422227443 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 8
[StartPage] => 115
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => octreotide
[Type] => general
)
[1] => Array
(
[SubjectFull] => octreotide LAR
[Type] => general
)
[2] => Array
(
[SubjectFull] => neuroendocrine tumor
[Type] => general
)
[3] => Array
(
[SubjectFull] => somatostatin analogue
[Type] => general
)
[4] => Array
(
[SubjectFull] => NETTER-1
[Type] => general
)
[5] => Array
(
[SubjectFull] => PROMID
[Type] => general
)
[6] => Array
(
[SubjectFull] => RADIANT-2
[Type] => general
)
[7] => Array
(
[SubjectFull] => Medicine (General)
[Type] => general
)
[8] => Array
(
[SubjectFull] => R5-920
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yau H
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kinaan M
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Quinn SL
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Moraitis AG
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 12
[Type] => published
[Y] => 2017
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 11775491
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => ume 11
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Biologics: Targets & Therapy
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |